Evidence map›Paper›PMID 41229673›Full record

ArticleResearch and practice in thrombosis and haemostasis2025

Neutrophil extracellular traps-targeting therapy with deoxyribonuclease 1 reduces large vessel occlusion-induced downstream microvascular thromboinflammation in a rat model of stroke.

Lucas Di Meglio, Mialitiana Solo Nomenjanahary, Laurine Bedoucha, Sebastien Dupont, Fatima Zemali, Véronique Ollivier, Clement Journe, Martine Jandrot-Perrus, Thomas Rambaud, Mikael Mazighi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lucas Di MeglioUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Mialitiana Solo NomenjanaharyUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Laurine BedouchaUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Sebastien DupontUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Fatima ZemaliUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Véronique OllivierUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Clement JourneUniversité Paris Cité and Université Sorbonne Paris Nord, Département de Recherche Cardiovasculaire, INSERM U1148, Laboratory for Vascular Translational Science (LVTS), Paris, France.
Martine Jandrot-PerrusUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Thomas RambaudUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Mikael MazighiUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Benoit Ho-Tin-NoeUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
Jean-Philippe DesillesUniversité Paris Cité, Faculté de Santé, Département de Pharmacologie, Optimisation Thérapeutique en Neuropsychopharmacologie, U1144 Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Neutrophil activation and neutrophil extracellular traps (NETs) participate in downstream microvascular thromboinflammation (DMT) and blood brain barrier disruption in acute ischemic stroke (AIS). Objectives: The aim of this study was to test whether deoxyribonuclease 1 (DNase 1) infusion, which cleaves extracellular DNA, could reduce DMT in a transient middle cerebral artery (MCA) occlusion stroke model in rats. Methods: Eighteen rats were subjected to 120-minute transient MCA occlusion. DNase 1 (3 mg/kg, 20% intravenous, and 80% intraperitoneal injection) or vehicle were randomly infused 30 minutes after MCA occlusion. Main outcome criteria were the infarct volume assessed with magnetic resonance imaging, neurological disability, and the rate of hemorrhagic transformation measured at 24 hours. Brain DMT was assessed with biomarkers of platelet, coagulation, and neutrophil activation quantified in brain homogenates. Results: The infusion of DNase 1 significantly reduced the infarct volume ( Conclusion: Our results confirm that NETs contribute to DMT during AIS and that early NET-targeting therapy may represent a new strategy to improve the clinical benefit of large vessel recanalization in AIS.

Indexed as

blood-brain barrierdeoxyribonuclease Iischemicmicrocirculationneutrophilsreperfusion injurystroke

Identifiers

PMID41229673
PMCPMC12603741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.